Company intelligence / Profile preview

Otivio

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

Otivio’s main product FlowOx™ has demonstrated increased blood flow to the lower extremities (~60% increase in small arteries and >100% in capillaries), reduced pain, improved wound healing, and potential reduction or elimination of amputations. Clinical and observational studies support its efficacy for PAD. Early data suggest possible benefit for MS symptoms

Therapeutic areas: NeurologyCardiovascularDermatology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

FlowOx

Commercial

Indications: Peripheral arterial disease, Multiple sclerosis, Diabetic foot ulcers, Intermittent claudication

Partnerships

None specifically listed; seeking commercial development partners

Beyond the preview

Go deeper on Otivio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otivio.

Explore the full profile